Technical Analysis for DMAC - DiaMedica Therapeutics Inc.

Grade Last Price % Change Price Change
grade C 3.28 -5.48% -0.19
DMAC closed down 5.48 percent on Thursday, November 21, 2019, on 57 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Up Down
See historical DMAC trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Calm After Storm Range Contraction -5.48%
NR7 Range Contraction -5.48%
Upper Bollinger Band Walk Strength -5.48%
Wide Bands Range Expansion -5.48%
Overbought Stochastic Strength -5.48%
Calm After Storm Range Contraction -11.11%

Older signals for DMAC ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
DMAC Chart by TradingView
Basic chart:
Profile
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Kidney Diseases Ischemia
Is DMAC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 14 DiaMedica Therapeutics Inc. 2019 Q3 - Results - Earnings Call Presentation
Nov 14 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2019 Results - Earnings Call Transcript
Nov 13 DiaMedica Therapeutics EPS beats by $0.01
Nov 13 DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update
Nov 13 DiaMedica Therapeutics (DMAC) Investor Presentation - Slideshow
Nov 13 The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
Nov 13 74 Biggest Movers From Yesterday
Nov 10 The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict
Nov 6 DiaMedica Therapeutics to Report Third Quarter 2019 Financials and Provide a Business Update November 14, 2019
Nov 5 DiaMedica Therapeutics to Participate in 10th Annual Craig-Hallum Alpha Select Conference
See more DMAC news...
Indicators
Indicator Value
52 Week High 6.53
52 Week Low 0.2588
Average Volume 40,693
200-Day Moving Average 3.2719
50-Day Moving Average 2.7102
20-Day Moving Average 3.147
10-Day Moving Average 3.43
Average True Range 0.3142
ADX 30.82
+DI 22.8136
-DI 18.5919
Chandelier Exit (Long, 3 ATRs ) 2.9374
Chandelier Exit (Short, 3 ATRs ) 3.5426
Upper Bollinger Band 3.842
Lower Bollinger Band 2.452
Percent B (%b) 0.6
BandWidth 44.16905
MACD Line 0.2383
MACD Signal Line 0.2171
MACD Histogram 0.0212
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.71
Resistance 3 (R3) 3.73 3.59 3.64
Resistance 2 (R2) 3.59 3.48 3.59 3.62
Resistance 1 (R1) 3.44 3.41 3.37 3.42 3.59
Pivot Point 3.30 3.30 3.27 3.30 3.30
Support 1 (S1) 3.15 3.19 3.08 3.14 2.97
Support 2 (S2) 3.01 3.12 3.01 2.94
Support 3 (S3) 2.86 3.01 2.92
Support 4 (S4) 2.85